Geriatric Medicine News

Although COVID-19 remained a popular topic among Healio Primary Care readers in 2021, other stories that discussed diabetes screening and physician suicide also generated significant attention.

The FDA has granted fast track designation for lecanemab, an investigational antiamyloid beta protofibril antibody used for treatment of patients in the early stages of Alzheimer’s disease.

Identifying and addressing risk factors for cognitive disorders shared within couples may reduce the risk for these disorders in the spouses of those with dementia, according to results of a prospective cohort study in JAMA Network Open.

As of Dec. 1, the FDA had approved 46 novel drugs this year, one fewer than it had approved by the same date in 2020.

Daily use of omega-3 in older adults at risk for depression correlated with a slight increase in depressive symptoms while having no effect on mood, according to a randomized clinical trial published in JAMA.

Biogen Inc. and Eisai Co. Ltd. announced plans to submit their phase 4 protocol for Aduhelm to the FDA in March 2022.

Severity in symptoms of late-life depression may be linked to geography, as well as racial/ethnic disparities depending on location, according to a cohort study published in The American Journal of Geriatric Psychiatry.

Fewer adults with multimorbidity had a “usual” clinician from whom they regularly sought care in 2016 compared with 2010, according to survey results published in JAMA Network Open.

Adults aged 50 years or older who received a Pfizer-BioNTech booster at least 5 months after a second dose of the vaccine had a 90% lower COVID-19 mortality rate compared with those who did not receive a booster.

Nearly 50% of individuals with incident mild cognitive impairment diagnoses were considered cognitively normal at follow-up, according to results of a community-based cohort study published in Neurology.